SeqOne Secures $20M Series A to Accelerate Genomics-Driven Personalized Healthcare

SeqOne Genomics, the trailblazing deep-tech company headquartered in Montpellier, France, is excited to announce a major milestone with a fresh funding round that raised €20,000,000. Founded in 2017, SeqOne has rapidly emerged as a leader in the genomics space by transforming complex genetic data into medically actionable insights, particularly in the fields of oncology and rare as well as inherited diseases. This significant investment not only validates the company's innovative approach but also paves the way for scaling its advanced clinical genomic analysis platform. Powered by explainable AI, the platform provides genomic laboratories and healthcare professionals with unparalleled accuracy, usability, and automation, seamlessly integrating across various lab technologies. As SeqOne continues to streamline multi-omics analysis workflows, this new capital will directly enhance research and development capabilities, fuel expansion into new markets, and further advance the company’s mission to make genetic testing as routine as traditional blood work. This, in turn, promises to radically improve patient outcomes by ushering in a new era of personalized healthcare at scale. Having already garnered several prestigious accolades, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize, and with two nominations for the esteemed Prix Galien award, SeqOne stands at the forefront of innovation. Esteemed investors such as Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club have shown their strong support for the company’s vision. With this recent funding, SeqOne is ready to accelerate its growth trajectory and continue transforming genomic data into actionable insights that save lives and enhance the quality of healthcare worldwide.